NCT03360747

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRx (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Akcea Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.

Conditions

• Familial Chylomicronemia Syndrome
• Lipoprotein Lipase Deficiency
• Hyperlipoproteinemia Type 1

Interventions

Type	Name	Description
DRUG	AKCEA-ANGPTL3-LRx	AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.

Timeline

• Start date: 2017-12-21
• Primary completion: 2018-06-12
• Completion: 2018-09-04
• First posted: 2017-12-04
• Last updated: 2021-01-07
• Results posted: 2021-01-07

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study